左卡尼汀联合多烯磷脂酰胆碱对酒精性肝病的疗效  

Therapeutic Efficacy of Levocarnitine Combined with Polyene Phosphatidylcholine on Patients with Alcoholic Liver Disease

作　　者：林松挺[1] 陈正义[1] 

机构地区：[1]海口市人民医院消化内科,海南海口570208

出　　处：《贵阳医学院学报》2015年第8期882-885,共4页Journal of Guiyang Medical College

摘　　要：目的:探讨左卡尼汀联合多烯磷脂酰胆碱治疗酒精性肝病患者的临床疗效。方法:选取酒精性肝病患者80例,随机分为治疗组与对照组,治疗组采用左卡尼汀与多烯磷脂酰胆碱联合治疗,对照组采用多烯磷脂酰胆碱治疗,疗程4周,观察治疗前后患者的症状体征、肝功能指标及肝脏纤维化指标的变化。结果:治疗4周后,对照组的总有效率为80.0%,对照组的总有效率为95.0%,两组比较差异有统计学意义(P<0.05);两组患者治疗前肝功能指标和肝纤维化指标无明显差异(P﹥0.05),治疗后与治疗前比较,差异有统计学意义(P<0.05);治疗4周后治疗组与对照组比较,肝功能指标和肝纤维化指标改善更加明显,差异有统计学意义(P<0.05)。结论:左卡尼汀联合多烯磷脂酰胆碱治疗酒精性肝病,能够有效改善患者肝功能以及延缓肝纤维化进程,值得临床推广使用。Objective：To investigate the clinical effects of levocarnitine combined with polyene phos-phatidylcholine on the treatment of alcoholic liver disease. Method：Eighty patients diagnosed with al-coholic liver disease were divided randomly into two groups,therapeutic group and control group. Therapeutic group received treatment of levocarnitine combined with polyene phosphatidylcholine, while control group was treated with polyene phosphatidylcholine treatment;both groups were treated for 4 weeks. The clinical symptoms and signs,liver functions tests and indexes of hepatic fibrosis were evaluated before and after treatment. Results：After 4 weeksˊtreatment,the therapeutic group got total effective rate of 95 . 0% which was obviously higher than that of control group（ 80 . 0%）,differences were statistical significant（ P﹤0 . 05 ）. The indexes of liver functions and hepatic fibrosis had no signif-icant differences before treatment（P﹥0. 05）. However,four weeksˊof treatment,comparing therapeu-tic group with control group,indexes of liver functions and hepatic fibrosis had ameliorated obviously, differences were statistically significant（ P﹤0 . 05 ）. Conclusion：Levocarnitine combined with polyene phosphatidylcholine as treatment for alcoholic liver disease can effectively improve liver function and inhibit the progress of hepatic fibrosis,which should be worthy of promotion.

关 键 词：肝疾病 酒精性 左卡尼汀 磷脂酰胆碱类 

分 类 号：R575[医药卫生—消化系统]